TIDMHCM
RNS Number : 9828W
Hutchison China Meditech Limited
24 April 2019
Results of Annual General Meeting
London: Wednesday, April 24, 2019: Hutchison China MediTech
Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that all
ordinary resolutions and special resolutions put to its Annual
General Meeting ("AGM") held on April 24, 2019 were duly passed.
The poll results of the resolutions were as follows:
Number of Votes (%)*
Resolutions For Against Withheld(#)
To consider and adopt the audited
financial statements and the reports
of the directors and independent
auditor for the year ended 31 December
1 2018. 60,078,559 233,957 1,332
(99.61209%) (0.38791%)
2(A) To re-elect Mr Simon To as a director. 55,000,510 2,112,677 3,200,661
(96.30089%) (3.69911%)
To re-elect Mr Christian Hogg as
2(B) a director. 60,226,266 86,649 933
(99.85633%) (0.14367%)
To re-elect Mr Johnny Cheng as a
2(C) director. 60,197,095 116,287 466
(99.80720%) (0.19280%)
2(D) To re-elect Dr Weiguo Su as a director. 60,200,656 112,989 203
(99.81266%) (0.18734%)
2(E) To re-elect Dr Dan Eldar as a director. 60,105,167 208,198 483
(99.65481%) (0.34519%)
2(F) To re-elect Ms Edith Shih as a director. 60,089,527 222,933 1,388
(99.63037%) (0.36963%)
To re-elect Mr Paul Carter as a
2(G) director. 60,309,174 3,701 973
(99.99386%) (0.00614%)
To re-elect Dr Karen Ferrante as
2(H) a director. 60,310,246 3,336 266
(99.99447%) (0.00553%)
To re-elect Mr Graeme Jack as a
2(I) director. 60,216,995 96,337 516
(99.84027%) (0.15973%)
To re-elect Professor Tony Mok as
2(J) a director. 60,313,056 359 433
(99.99940%) (0.00060%)
To re-appoint PricewaterhouseCoopers
as the auditor of the Company and
authorise the board of directors
3 to fix the auditor's remuneration. 60,309,718 3,922 208
(99.99350%) (0.00650%)
To increase the authorised share
4 capital. 58,172,894 2,140,527 427
(96.45099%) (3.54901%)
To grant a general
mandate to the
directors of the
Ordinary Resolution Company to issue
5 No. 5(A) : additional shares. 58,378,604 1,934,441 803
(96.79267%) (3.20733%)
To disapply pre-emption
Special Resolution rights (general
No. 5(B) : power). 59,336,430 973,921 3,497
(98.38515%) (1.61485%)
To disapply pre-emption
rights (in connection
Special Resolution with an equity
No. 5(C) : raise). 48,922,239 11,387,728 3,881
(81.11800%) (18.88200%)
To grant a general
mandate to the
directors of the
Company to repurchase
Ordinary Resolution shares of the
No. 5(D) : Company. 60,312,021 1,694 133
(99.99719%) (0.00281%)
* Percentages rounded to 5 decimal places
(#) A vote withheld is not a vote in law and is not counted in
the calculation of the proportion of the votes for and against a
resolution.
As at the date of the AGM, the number of issued shares of
Chi-Med was 66,657,745, which was the total number of shares
entitling the holders to attend and vote on the ordinary
resolutions and special resolutions proposed at the AGM.
About Chi-Med
Chi-Med (AIM/Nasdaq: HCM) is an innovative biopharmaceutical
company which researches, develops, manufactures and markets
pharmaceutical products. Its Innovation Platform, Hutchison
MediPharma, has about 420 scientists and staff focusing on
discovering, developing and commercializing targeted therapeutics
and immunotherapies in oncology and autoimmune diseases. It has a
portfolio of eight cancer drug candidates currently in clinical
studies around the world. Chi-Med's Commercial Platform
manufactures, markets, and distributes prescription drugs and
consumer health products, covering an extensive network of
hospitals across China.
Dual-listed on the AIM market of the London Stock Exchange and
the Nasdaq Global Select Market, Chi-Med is headquartered in Hong
Kong and majority owned by the multinational conglomerate CK
Hutchison Holdings Limited (SEHK: 1). For more information, please
visit: www.chi-med.com.
CONTACTS
Investor Enquiries
Mark Lee, Senior Vice President, Corporate Finance & Development +852 2121 8200
Annie Cheng, Vice President, Corporate Finance & Development +1 (973) 567 3786
David Dible, Citigate Dewe Rogerson +44 7967 566 919 (Mobile)
david.dible@citigatedewerogerson.com
Xuan Yang, Solebury Trout +1 (415) 971 9412 (Mobile)
xyang@troutgroup.com
Media Enquiries
UK & Europe - Anthony Carlisle, Citigate Dewe Rogerson +44 7973 611 888 (Mobile)
anthony.carlisle@cdrconsultancy.co.uk
Americas - Brad Miles, Solebury Trout +1 (917) 570 7340 (Mobile)
bmiles@troutgroup.com
Hong Kong & Asia ex-China - Joseph Chi Lo, Brunswick +852 9850 5033 (Mobile)
jlo@brunswickgroup.com
- Zhou Yi, Brunswick +852 9783 6894 (Mobile)
yzhou@brunswickgroup.com
Mainland China - Sam Shen, Edelman +86 136 7179 1029 (Mobile)
sam.shen@edelman.com
Nominated Advisor
Richard Gray / Atholl Tweedie, Panmure Gordon (UK) Limited +44 (20) 7886 2500
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RAGLZLFLKZFEBBB
(END) Dow Jones Newswires
April 24, 2019 08:54 ET (12:54 GMT)
Hutchmed (china) (LSE:HCM)
Historical Stock Chart
From Apr 2024 to May 2024
Hutchmed (china) (LSE:HCM)
Historical Stock Chart
From May 2023 to May 2024